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A B S T R A C T
We demonstrated here thanks to proteomic, that proprotein convertase 1/3 knockdown macrophages
present all the characteristic of activated pro-inﬂammatory macrophages. TLR4 and TLR9 signaling
pathways can be enhanced leading to the secretion of pro-inﬂammatory factors and antitumor factors.
We can control their activation by controlling one enzyme, PC1/3. In a tumor context, PC1/3 inhibition in
macrophages may reactivate them and lead to a cytokine storm after stimulation “at distance” with a TLR
ligand. Therefore, we name these proprotein convertase inhibited macrophages the “drone macro-
phages”. They constitute an innovative cell therapy to treat efﬁciently tumors.
ã 2016 The Authors. Published by Elsevier B.V. on behalf of European Proteomics Association (EuPA). This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Contents lists available at ScienceDirect
EuPA Open Proteomics
journal home page: www.elsevier .com/ locat e/euprotMacrophages are involved in almost every disease. They are
recruited during inﬂammation to exert their inﬂammatory and
phagocytosis functions. Tissue-resident macrophages are not a
homogenous population. In fact, they present different phenotypes
which can be inﬂuenced by their environment. Macrophages
activation is often represented in two ways: M1 pro-inﬂammatory
and M2 anti-inﬂammatory polarization. This description is over-
simpliﬁed because macrophages activation depends on many
parameters such as their origin, environment etc. During
tumorigenesis, macrophages are recruited to the tumor site to
become tumour associated macrophages (TAMs). However, the
tumor creates an immune suppressive environment, which orients
TAMs toward the anti-inﬂammatory M2 phenotype. One challenge
is to counteract this local immune suppression observed in
numerous cancers. More and more therapies are being developed
in order to ﬁnd a way to control macrophages’ phenotype
switching in order to boost the immune response in cancer
patients. Pro-inﬂammatory macrophages can be activated byAbbreviations: PC, proprotein convertase; TAM, tumor associated macrophages;
TLR, toll like receptor; KD, knockdown; NT, non-target; LPS, lipopolysaccharides;
MVB, multivesicular bodies; CCL, chemokine (C–C motif) ligand; CXCL, chemokine
(C–X–C motif) ligand.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).several stimuli triggering signaling cascades. As stimuli, we can
ﬁnd Toll-like receptors (TLR) ligands (LPS, CpG-ODN, Taxol . . . ).
TLR-based therapies could be thus very interesting.
Our research goes in that direction. In fact, we work on an
enzyme called proprotein convertase 1/3 (PC1/3). PC1/3 was ﬁrst
associated with the neuroendocrine system. More recent studies
have demonstrated that this enzyme is also expressed in immune
cells like macrophages and lymphocytes. In PC1/3 knockout mice, a
massive cytokine response was registered following the stimula-
tion of TLR4 [1]. Another study conﬁrmed the role of PC1/3 in
cytokines release in rat alveolar NR8383 macrophages [2]. In the
present study, we want to know the impact of PC1/3 knockdown
(KD) on NR8383 macrophages activation after TLR4 (LPS) and TLR9
(CpG-ODN) stimulations. We used a complete proteomic approach
to answer this question. In the ﬁrst part, a shotgun experiment was
performed on the macrophages supernatants stimulated with LPS
from 1 h to 72 h. More than 1400 proteins were identiﬁed and
18 proteins were speciﬁc to PC1/3 inhibition. Some of them are
involved in Th1-cell activation and inﬂammatory response. We
also identiﬁed immune factors such as danger signals, cytokines
and chemokines which are secreted by PC1/3 KD macrophages
earlier compared to non-target shRNA (NT) macrophages [3]. We
then focused on the secretion of chemokines and cytokines by
cytokines arrays and conﬁrmed the fact that PC1/3 KD macro-
phages secrete more pro-inﬂammatory factors such as IL6, TNF-a,
CXCL10, IL-1a and b. After LPS treatment, the secretion of some of
these factors was enhanced. Interestingly, the stimulation withics Association (EuPA). This is an open access article under the CC BY-NC-ND license
Fig. 1. Schematic depicting how PC1/3 knockdown impacts macrophage activation. PC1/3 knockdown promotes the formation of endosomes and MVB release of
inﬂammatory chemokines and cytokines via the non-canonical secretion pathway (1). Danger signal molecules (DAMs) can activate TLR4 and TLR9 (2) and induce the MyD88-
dependent pathway with increased NF-kB (3) nuclear translocation (4) linked to Ca2+mobilization in PC1/3 KD macrophages (5). Both of these phenomena are also implicated
in cytokines, chemokines, DAMs and tumor viability inhibitor release as well as cytoskeletal rearrangements leading to the formation of ﬁlopodia (6). We then noticed that
during LPS challenge, the loop was ampliﬁed and driven toward the induction of increased Ca2+ release from the ER, greater numbers of ﬁlopodia and MVBs, the release of
additional immune factors and a greater number of anti-tumor factors. Under ODN-CpG challenge, we observed that PC1/3 moved rapidly to CpG-ODN-containing endosomes
and lysosomes and subsequently co-localized with TLR9. In PC1/3 knockdown macrophages, compartmentalization of TLR9 was altered, and formed clusters at the cell
periphery. Under CpG-ODN treatment, PC1/3-KD macrophages secreted more pro-inﬂammatory cytokines (TNF-a, CXCL2, and IL1a) and less CCL5 and CXCL10. We have thus
established that PC1/3 inhibition clearly affects TLR9 trafﬁcking and signaling and not its activation. All experimental procedures have been published in [3].
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observed under LPS. In fact, PC1/3 KD macrophages secrete more
CXCL2 and IL1-a. One important observation was that PC1/3 KD
macrophages secretomes, obtained after LPS stimulation, have an
antitumor activity on breast (SKBR3) and ovarian (SKOV3) cancer
cells, meaning that these macrophages secrete killing factors [3].
To understand why such secretion is observed in PC1/3 KD
macrophages, we studied the intracellular proteins by mass
spectrometry. The ﬁrst ﬁnding from these proteomic data was
the big impact of PC1/3 knockdown on the cytoskeleton. Co-
expression network analysis showed that actin-related proteins
and exosomal proteins were overexpressed in PC1/3 KD macro-
phages. A complete reorganization of the cytoskeleton was
highlighted with the development of a lot of ﬁlopodia in PC1/
3 KD cells leading us to afﬁrm that macrophages are more active
when PC1/3 is inhibited. This cytoskeleton reorganization has a
huge impact on the formation of multivesicular bodies (MVB) and
the trafﬁcking of some proteins such as the TLR9 receptor [4]. In
fact, immunoﬂuorescence studies showed that TLR9 trafﬁcking is
modulated in PC1/3 KD macrophages and is aggregated within
MVB. The higher number of MVB and exosomes can be one
explanation for the cytokines release observed in PC1/3 KD
macrophages. Moreover, calcium homeostasis is also modulated as
a consequence of cytoskeleton rearrangement. Basal calcium
concentration is higher in PC1/3 KD macrophages compared to
NT macrophages and increases following LPS stimulation. Calcium
and cytokines release are often linked. Furthermore, calcium can
also inﬂuenced the TLR signaling pathway. We investigated
TLR9 and TLR4 signaling pathways by studying the level of
degradation of IkB-a after LPS or CpG-ODN stimulation. We
noticed that the NF-kB transcription factor is enhanced in bothcases in PC1/3 KD macrophages. By proteomic, we also demon-
strated that the two pro-inﬂammatory transcription factors
STAT1 and STAT2 are over-expressed whereas the level of
phosphorylation of STAT3, which is known to inhibit NF-kB
signaling, is lower in PC1/3 KD macrophages. This last point could
be interesting because STAT3 is a known target in immunotherapy
of cancer.
In this study, we demonstrated, thanks to proteomic, that PC1/
3 KD macrophages present all the characteristic of activated pro-
inﬂammatory macrophages. We are able to enhance TLR4 and
TLR9 signaling pathways leading to the secretion of pro-
inﬂammatory factors and antitumor factors (Fig. 1). We can
control their activation by controlling one enzyme, PC1/3. In this
perspective, it should be interesting to verify our concept on other
TLR. In a tumor context, PC1/3 inhibition in macrophages may
reactivate them and lead to a cytokine storm after stimulation “at
distance” with a TLR ligand. Therefore, we name these PC1/
3 inhibited macrophages the “drone macrophages”. They consti-
tute an innovative cell therapy to treat efﬁciently tumors.
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